09/ 11/ 2026
NMPA Releases 2026 Revised Inspection Guidelines for Drug Clinical Trials
NMPA’s 2026 revised clinical trial inspection guidelines strengthen sponsor oversight, data governance, quality management, and risk-based compliance.
09/ 04/ 2026
FDA Issues 55 Draft Product-Specific Guidances, Further Clarifying Generic Drug Development Pathways
FDA’s latest 55 draft PSGs clarify generic drug development, BE strategies, complex products, and regulatory pathways for global pharmaceutical companies.
08/ 31/ 2026
Loncom Pharma Visits CPHI Korea 2026 to Strengthen Pharmaceutical Partnerships in East Asia
Loncom Pharma visited CPHI Korea 2026 to engage with pharmaceutical partners, understand East Asian market needs, advance international collaboration.
